“By leveraging the editorial excellence of ‘The Pink Sheet,’ the leading information source for U.S. pharmaceutical industry information since 1939 into the Asian markets and combining it with new features enabled by Web 2.0 technology, we believe PharmAsiaNews.com will become an important information service to multinational pharmaceutical companies who are making increasingly larger bets in the region,” said Gerry Stoia, V.P. of Elsevier Health Science Division’s Pharma Solutions unit and President of F-D-C Reports, Inc.

“Increasingly over the past several years, customers have requested reliable, independent and accurate ‘Pink Sheet like’ coverage of business and regulatory developments in the APAC region. F-D-C Reports, Inc. has answered the call for information on developments in China, India, Japan and other countries in the region via our PharmAsiaNews.com service,” Stoia added.

The result is a publication that provides readers with the broadest spectrum of news sources, including: original on-the-ground reporting from news bureaus across Asia; guest columns; exclusive interviews; news summaries; English translation summaries of Chinese- and Japanese-language news; and aggregated content from around the globe.

“What makes PharmAsiaNews.com unique is our commitment to original local market coverage and insights developed by local staff who are resident in the market. This is not a service that provides solely rewritten press releases and translated local language stories. By leveraging Elsevier’s global footprint, we’ve brought local talent aboard to provide our customers with the ‘boots on the ground’ coverage our customers have requested,” said Joe Hecker, Editor-in-Chief at Elsevier’s F-D-C Reports, Inc.

Subscribers to PharmAsiaNews.com get online access to around-the-clock coverage of the rapidly expanding Asia marketplace, including China, India, Japan and other nations in the Pacific Rim; twice-weekly email updates; full archive access; breaking news alerts; and other online resources.

About F-D-C Reports

F-D-C Reports, Inc. provides up-to-date information about the worldwide health care industry via its publications including The Pink Sheet®, The Gray Sheet®, The Rose Sheet®, The Tan Sheet®, and Pharmaceutical Approvals Monthly. The publications are read extensively by pharmaceutical and healthcare executives, policy-makers, and analysts seeking to understand the developments affecting the U.S. regulation and marketing of healthcare products and services. F-D-C Reports, Inc. has one of the largest, most experienced, and most respected editorial teams reporting on the latest regulatory, legislative, and business news affecting the U.S. drug, biotechnology, medical device, nonprescription drug, nutritionals, and cosmetics industries. F-D-C Reports, Inc. is part of Elsevier.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier’s 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.

Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).